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Background. Smoking has a detrimental eﬀect in Crohn’s disease (CD), but this may be due to factors in smoking other than
nicotine. Given that transdermal nicotine benefits ulcerative colitis (UC), and there is a considerable overlap in the treatment
of UC and CD, the possible beneficial eﬀect of nicotine has been examined in patients with Crohn’s colitis. Aims. To assess the
eﬃcacy and safety of nicotine enemas in active Crohn’s colitis. Patients. Thirteen patients with active rectosigmoid CD; 3 patients
were excluded because they received antibiotics. Methods. Subjects were given 6 mg nicotine enemas, each day for 4 weeks, in an
open pilot study. At the beginning and end of the trial, a Crohn’s disease activity index (CDAI) score was calculated, sigmoidoscopy
was performed, and haematological inflammatory markers measured. Results. Mean CDAI decreased from 202 to 153—the score
was reduced in 6 patients, unchanged in 3, and increased in one. Frequency of bowel movements decreased in 8 patients and the
sigmoidoscopy grade was reduced in 7. Mean C-reactive protein decreased from 22.0 to 12.3 mg/L. There were no withdrawals due
to adverse events. Conclusions. In this relatively small study of patients with active Crohn’s colitis, 6 mg nicotine enemas appeared
to be of clinical benefit in most patients. They were well tolerated and safe.
Copyright © 2008 J. R. Ingram et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1. INTRODUCTION
It is a remarkable epidemiological observation that whilst
ulcerative colitis (UC) is related to nonsmoking [1–4], the
opposite applies to Crohn’s disease (CD). Patients with CD
are more often smokers compared with the general popu-
lation [5], and smoking has an adverse eﬀect on the course
of their disease [6]. Several mechanisms for this could be
relevant; components of tobacco smoke, such as oxidizing
chemicals, which, unlike nicotine, have prothrombotic ef-
fects, could exacerbate microvasculature abnormalities and
ischaemia of the bowel wall [7]. It has also been suggested
that CD could be caused by an impaired host response to lu-
minal bacteria; this, in turn, could be exacerbated by the im-
munosuppressive eﬀects of smoking on macrophages [8, 9].
It is likely that diﬀerent mechanisms are responsible for the
“opposite eﬀects” of smoking in CD and UC, which are in
many other respects similar diseases. The eﬀects of smoking
should not be considered synonymous with nicotine. Nico-
tine, as opposed to smoking, may have a beneficial eﬀect in
patients with Crohn’s colitis, given that there is a considerable
overlap in the treatments for the two conditions and nicotine
has been shown to be of benefit in UC. Although the specific
mechanisms underlying this eﬀect remain unclear, nicotine
has a number of actions that could be potentially beneficial,
including eﬀects on the immune system [10] and gut motility
[11].
A recent Cochrane Review [12] has confirmed benefit
from transdermal nicotine in active UC: a meta-analysis of
two eligible randomized placebo-controlled trials [13, 14] so
far performed showed that after 4 to 6 weeks treatment, 19
of 71 patients treated with transdermal nicotine were in re-
mission compared to 9 of 70 given placebo (odds ratio 2.56,
95% confidence interval 1.02–6.45). A nicotine enema has
also been developed and found to be of benefit when given as
additional therapy in two uncontrolled pilot studies in active
distal UC [15, 16], but not in a recent randomised controlled
trial [17]. A phase I-II trial of delayed release oral nicotine
has shown promise [18] but a controlled trial is awaited.
The aim of this open pilot study was to examine the ef-
ficacy and safety of nicotine enemas in active distal Crohn’s
colitis.
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2. MATERIALS AND METHODS
2.1. Patients
Patients with CD, based on the clinical, endoscopic, and
histological features of Lennard-Jones’ criteria [19], were
recruited from the gastroenterology outpatient department
of a single centre; the key selection criteria were clinical and
sigmoidoscopic evidence of active disease in the rectosig-
moid region. Although the presence of CD in other regions
of the gastrointestinal tract was permitted, the patient’s prin-
cipal clinical problem had to relate to active distal colitis. Pa-
tients were not enrolled if they were current smokers, had
other unstable medical problems, were pregnant or lactating,
had used enemas in the previous week, had changed their
CD therapy with mesalazine, steroids, or antibiotics within
the last 2 weeks, or had changed immunosuppressive ther-
apy with azathioprine in the previous 3 months. The dosage
of all concomitant medications was kept unchanged during
the study period.
2.2. Study design
This was an open pilot study of 4 weeks’ duration in
which nicotine enemas were given as additional therapy—
subjects continued their conventional treatment without
change during the study period. Each 100 mL liquid en-
ema contained 6 mg of nicotine complexed with 400 mg of
the high molecular weight polyacrylic acid carbomer, Car-
bopol 974P (Goodrich, UK), as already described [20]. At
the time of enrolment, a record was made of the patient’s
symptoms of colitis including stool frequency, abdominal
pain, general well being, any complications of CD and ur-
gency of defaecation; the latter was graded as none, mild,
moderate, or severe enough to cause incontinence. Although
Crohn’s colitis may be patchy, sigmoidoscopy with a biopsy
of the most inflamed area was also performed by the same
investigator in each case. Patients were also asked to com-
plete an inflammatory bowel disease quality of life ques-
tionnaire (SIBDQ) [21] and blood tests were taken for a
full blood count, liver and renal function, and inflammatory
markers.
During the study, patients kept a diary of their bowel
symptoms and any adverse events (AEs). The patients were
assessed at the end of the 4-week trial period, or at prema-
ture withdrawal, or at any other time at the patient’s request.
The initial assessments were repeated by the same physician.
Sigmoidoscopy with a biopsy, again from the most inflamed
area, was repeated.
2.3. Outcome measures
The main outcome measures used were clinical improvement
as measured by Crohn’s disease activity index (CDAI) [22],
and changes in bowel frequency and urgency of defaeca-
tion. Urgency was included because it is a useful guide to the
severity of inflammation in distal colitis. At sigmoidoscopy,
the severity of inflammation of the worst aﬀected area was
graded visually according to the system described by Dick
et al. [23]. The biopsy specimens were stained with haema-
toxylin and eosin and graded by one histopathologist (GTW)
according to the Truelove and Richards system [24] adapted
for Crohn’s colitis, see Table 1.
2.4. Ethical considerations
This study was approved by the Bro Taf Local Research Ethics
Committee.
3. RESULTS
Of the 13 patients recruited, 3 were excluded because they
were also given antibiotics for a chest infection, a middle
ear infection, and recurrence of a finger infection during the
study period. Demographic details of the remaining 10 pa-
tients are in Table 2; 7 were male and the mean age was 52
years. Seven patients were exsmokers whilst the remainder
had never smoked. The mean duration of disease relapse was
45 weeks and in 4 patients was greater than 99 weeks. Half
of the patients were on concomitant oral 5-ASAs, 2 were on
prednisolone (10 mg) and 2 were on azathioprine; several pa-
tients had been intolerant of thiopurines. Only one patient
had recently taken enemas, asacol foam. The mean baseline
CDAI score was 202 (SD 80, range 73 to 348). In addition to
their colonic involvement, one patient also had small bowel
CD. Three patients had disease limited to the left side of the
colon.
3.1. Efficacy
Patient 10 withdrew from the study after only 2 weeks due to
failure to respond to treatment, but was kept in the intention-
to-treat analysis; she had the highest CDAI score (348) at
baseline; all other patients completed 4 weeks’ treatment.
Changes in the main outcome measures for each patient are
in Figure 1. The mean CDAI score decreased from 202 to
153—the score was reduced in 6 patients, unchanged in 3,
and increased in one patient. The frequency of bowel move-
ments each day was reduced in 8 patients and unchanged in
2, and the urgency to defaecate was reduced in 7 patients, in
one case from severe to nil, and was unchanged in the other 3.
The sigmoidoscopy score improved in 7 patients and was un-
changed in 3, but changes in histology showed no clear trend
with a wide variation in the baseline scores. One of the two
patients taking oral steroids improved suﬃciently to consider
a gradual reduction of the dose after the study.
The mean SIBDQ score increased from 39 to 47. Mean
levels of the inflammatory markers C-reactive protein (CRP),
erythrocyte sedimentation rate (ESR), and fibrinogen all
fell from 22.0 mg/L, 19.1 mm/h, and 4.4 g/L, respectively,
to 12.3 mg/L, 12.5 mm/h, and 4.0 g/L, respectively, whilst
the mean white cell count was unchanged at 8.4× 109/L
and the mean platelet count increased slightly from 310 to
320× 109/L. Renal function and liver function tests were un-
aﬀected.
The eﬀect of disease location on outcome was briefly con-
sidered. The only patient with ileal disease improved during
the study, with a CDAI reduction from 150 to 74. Of the 3 pa-
tients with disease restricted to the left colon, one improved,
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Figure 1: Outcome measures. Response of 10 patients with active Crohn’s colitis given 6 mg nicotine enemas daily for 4 weeks. Where 2 or
3 patients had the same baseline and end values, this is indicated above the connecting line, which is drawn more boldly. CDAI is Crohn’s
disease activity index. Frequency is the number of stools/24 hours. Urgency of defaecation is graded: 0 = none, 1 = mild, 2 = moderate, and
3 = severe enough to cause incontinence. Sigmoidoscopic score is graded 0, normal to 4, fulminant disease. Histological scores are based on
acute inflammatory activity: grade 0, no polymorphs to grade 4, florid acute inflammation with polymorphs and ulceration. Histology data
is given for only 8 patients because the end-of-study biopsies of 2, both with baseline scores of 2, were insuﬃcient for analysis. QOL is a score
of quality of life as measured by the short inflammatory bowel disease questionnaire [21]. Paired data were available for CRP in 7 patients
and for ESR in 8 patients.
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Table 1: Histological grade of inflammation. The histological grade of inflammation present in biopsies taken from the most inflamed area
of the rectosigmoid region at sigmoidoscopy, adapted by GTW for Crohn’s colitis from the system described by Truelove and Richards [24]
for ulcerative colitis.
Grade of inflammation Description
0 No polymorphs
1 Small number of polymorphs in the lamina propria with minimal cryptitis
2 Focal cryptitis with crypt rupture or aﬀecting groups of two or more adjacent crypts
3 Florid diﬀuse polymorph infiltrate with crypt abscesses
4 Florid acute inflammation with ulceration
Table 2: Baseline characteristics of 10 patients with Crohn’s colitis. Extent of disease: 1 = proctitis, 2 = sigmoid colon, 3 = descending colon,
4 = transverse colon, 5 = ascending colon, 6 = pancolitis, 7 = ileal, 8 = perianal. “Recent enemas” refers to any steroid or 5 aminosalicylate
(5-ASA) enemas taken from 1 to 3 weeks before entry into the study. All concomitant medication doses given are the daily amounts, the only
oral steroid taken was prednisolone, aza = azathioprine. CDAI = Crohn’s disease activity index.
No. Age
(years)
Sex Exsmoker Disease
extent
Duration
relapse
(weeks)
Recent
enemas
5-ASA
(g)
Oral
steroids
(mg)
Aza
(mg)
Baseline
CDAI
score
1 41 M − 1,2,3,4 >99 − − − − 73
2 27 M + 1 1 − − − − 156
3 52 F + 6,7 >99 − − 10 − 150
4 59 M + 2,5 7 − 3.2 − 150 246
5 73 M + 6 >99 − 2.4 10 − 200
6 38 M − 6,8 9 − − − − 167
7 59 F + 2,3,4 >99 − 1.2 − − 272
8 79 M + 3,4 30 − − − − 259
9 27 M − 1 1 − 3.0 − − 144
10 62 F + 2,3 5 foam 2.4 − 50 348
one remained the same, and the other deteriorated; the re-
spective changes in CDAI score were from 144 to 67, from
348 to 345, and from 156 to 189. In terms of the duration of
disease relapse, of the 4 patients who had been in relapse for
more than 99 weeks, 3 improved, with CDAI changes from
272 to 169, from 200 to 64, and from 150 to 74, whilst one
remained the same, with a CDAI change from 73 to 71.
3.2. Safety
Eight of the 10 patients experienced an adverse event but
none were classified as serious. In total, 12 AEs were reported
(Figure 2) and 11 of these were thought to be related to nico-
tine, the other being a localised skin rash that resolved spon-
taneously. Two-thirds of the AEs occurred on commence-
ment of treatment and were temporary, lasting 2 days or
less. The most common AE was diﬃculty sleeping, which in-
cluded vivid dreams, reported by 4 patients. The other AEs
were lightheadedness, nausea, and headache.
4. DISCUSSION
These are the first observations of topical nicotine in patients
with active Crohn’s colitis. In the 10 patients, there was a
Rash-1
Sleep prob-4
Nausea-2
Headache-3
Lightheaded-2
Figure 2: Adverse events during study. Adverse events experi-
enced during nicotine enema treatment with the number of pa-
tients aﬀected in each case. “Sleep prob” refers to disturbed sleep or
vivid dreams. The “rash” was a 2 cm diameter erythematous macu-
lopapular lesion on the forearm of a patient which resolved sponta-
neously.
CDAI reduction in 6 and an increase in one; the mean score
decreased from 202 to 153. Frequency of bowel movements
was reduced in 8 patients, urgency to defaecate was reduced
in 7, and the sigmoidoscopy score improved in 7; the mean
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SIBDQ score increased from 39 to 47. Clinical improvement
was noted in patients who also had disease in locations other
than the rectosigmoid, including the one patient with small
bowel disease. Three of the 4 patients with chronically active
disease for more than 99 weeks improved. There were no se-
rious AEs and no premature withdrawals due to intolerance.
A relatively small open pilot study of this nature can only
provide preliminary data on eﬃcacy and safety. Hence, al-
though our observations suggested improvement in most of
the patients, and certainly no overall deterioration, the find-
ings will need to be corroborated by larger randomised con-
trolled studies. Formal tests of significance were not per-
formed because, in this relatively small study, they may have
been misleading. Initially, it was planned to recruit 20 pa-
tients to the study, but recruitment was slow for two main
reasons; 10 patients with active Crohn’s colitis, who were
identified as suitable for entry to the study, were current
smokers and therefore excluded. In addition, because the
study preparation was an enema, those patients whose prin-
cipal symptoms were related to left-sided active colitis were
targeted. However, identifying such a homogenous group
proved hard, as a number of patients screened had to be ex-
cluded because they had symptoms that related primarily to
other sites of disease involvement. This may have reduced
potential sources of error from our study, but it will prob-
ably make it diﬃcult to recruit suﬃcient numbers to achieve
a larger study of homogeneous patients, as defined by the Vi-
enna classification [25]. For this small pilot study, full Vienna
classification of patients was not performed and subgroup
analyses were avoided.
It is noteworthy that methods used to assess the re-
sponse of Crohn’s colitis to treatment have some limitations.
The patchy nature of Crohn’s colitis means sigmoidoscopy
and histology findings should be interpreted with caution.
The separate recording and analysis of stool frequency and
urgency of defaecation was an attempt to assess some of
the more troublesome symptoms of distal colitis, although
a contribution from more proximal disease cannot be ex-
cluded. This was used in addition to the global assessment
provided by the CDAI, the more conventional composite
scoring system of disease activity that contains systemic fea-
tures less relevant to this study. Two of the 10 patients had a
CDAI score less than 150 at study entry, which might imply
disease remission; however, all patients had rectosigmoid in-
flammation on sigmoidoscopy and had symptoms of active
distal disease.
The negative association between smoking and CD raises
questions about whether topical nicotine is an appropriate
treatment for patients with Crohn’s colitis. However, this was
justified on the basis that the treatments for UC and CD are
very similar, and transdermal nicotine has been found to pro-
vide benefit in UC. It is possible that the detrimental eﬀect of
smoking on CD is mediated through mechanisms indepen-
dent of nicotine; these could, for example, include exacer-
bation of underlying ischaemia of the bowel wall at the mi-
crovascular level [7] due to prothrombotic oxidizing chemi-
cals present in tobacco smoke. It has also been suggested that
CD could be caused by an impaired host response to luminal
bacteria; this, in turn, could be exacerbated by the immuno-
suppressive eﬀects of smoking on macrophages [8, 9]. These
eﬀects could mask any benefit from nicotine in Crohn’s col-
itis. It is also possible that the response to nicotine diﬀers
between ileal and colonic diseases. Rectal enema treatment
of the transmural inflammation of Crohn’s colitis is not well
described in the literature, however it is used in clinical prac-
tice.
Possible mechanisms for a therapeutic eﬀect of topical
nicotine in distal colitis include alterations in colonic motil-
ity. Nicotine has been shown to reduce tone and muscular ac-
tivity in the sigmoid colon [11], an eﬀect mediated primarily
through nitric oxide that is released by nicotine [26]. Another
potential mechanism is via a reduction in mucosal tumour
necrosis factor (TNFα), a key cytokine in the generation of
inflammation in CD [27]. Nicotine has been found to reduce
the secretion of TNFα from macrophages, by activation of α7
nicotinic acetylcholine receptors [28].
Our pilot study has shown that, in the 10 patients with
active Crohn’s colitis, 6 mg nicotine enemas were associated
with clinical improvement in the majority of patients, they
were safe and well tolerated, and did not appear to worsen the
condition. Larger randomised controlled trials are needed to
confirm these observations and longer-term outcome data
would also be of interest.
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